Treatment options (ERT, substrate reduction, chaperones)

Enzyme Replacement Therapy (ERT) - The Protein Push

• Mechanism: Regular intravenous (IV) infusions of recombinant human enzymes to replace the deficient lysosomal protein.
• Targeting: Enzymes are engineered with a mannose-6-phosphate (M6P) "tag." This allows them to bind to M6P receptors on cell surfaces, triggering endocytosis and delivery to the lysosome.
  • Think of it as a specific postal code for the lysosome.
• Examples:
  • Gaucher Disease: Imiglucerase (recombinant glucocerebrosidase).
  • Fabry Disease: Agalsidase beta (recombinant α-galactosidase A).
  • Pompe Disease: Alglucosidase alfa (recombinant acid α-glucosidase).
• Limitations:
  • High cost & lifelong treatment.
  • Risk of infusion reactions and antibody formation against the enzyme.
  • Ineffective for tissues with poor vascular access (e.g., bone, cartilage).

⭐ High-Yield: ERT does not cross the blood-brain barrier (BBB). It primarily addresses visceral and systemic symptoms, but fails to treat or prevent progressive neurological damage in neuronopathic LSDs.

Substrate Reduction (SRT) - Less In, Less Mess

• Principle: If the "garbage" (substrate) can't be broken down, produce less of it. SRT works by inhibiting an enzyme upstream in the metabolic pathway, leading to ↓ synthesis of the accumulating substrate.
• Analogy: 📌 Like turning down the faucet to a slow-draining sink. You're easing the burden on the faulty lysosomal "drain."
• Clinical Use: An oral therapy option, often for milder disease forms or when ERT is unsuitable.

• Key Agents:
  • Miglustat: Used for Gaucher disease (type 1) and Niemann-Pick disease (type C).
  • Eliglustat: A first-line oral therapy for most patients with Gaucher disease (type 1).

⭐ Pharmacogenomic Pearl: Eliglustat metabolism is highly dependent on CYP2D6. Patients must be genotyped before starting therapy to determine their metabolizer status (e.g., poor, extensive, ultra-rapid) and guide appropriate dosing.

Chaperone Therapy - The Folding Fix

• Mechanism: Small-molecule drugs that selectively bind to a patient's specific misfolded lysosomal enzyme.

  • Acts as a folding scaffold, stabilizing the protein's correct 3D conformation.
  • This prevents its premature degradation in the endoplasmic reticulum.
  • Facilitates proper trafficking to the lysosome, restoring partial enzyme function.

• Clinical Use: Best for specific missense mutations where a protein is made, just unstable.

  • Migalastat: For Fabry disease (α-galactosidase A).
  • Ambroxol: For Gaucher disease (glucocerebrosidase).

⭐ High-Yield Pearl: Unlike ERT, some chaperones can cross the blood-brain barrier, offering a potential treatment for neurologic symptoms of certain LSDs.

High-Yield Points - ⚡ Biggest Takeaways

• Enzyme replacement therapy (ERT) provides a functional enzyme intravenously; it mainly treats systemic symptoms of diseases like Gaucher & Fabry.
• Substrate reduction therapy (SRT) (e.g., Miglustat, Eliglustat) orally inhibits the synthesis of accumulating substrates.
• Chaperone therapy (e.g., Migalastat for Fabry disease) binds and stabilizes specific mutant enzymes, aiding proper folding and trafficking.
• ERT cannot cross the blood-brain barrier, limiting its use for neurological symptoms.